New genomic markers for improved decision making in the prostate cancer active surveillance era

Active surveillance (AS) for men with low risk prostate cancer (PCa) has emerged as one of the accepted management options over the last decade. Even though it has been widely implemented, the process of selecting appropriate patients remains somewhat ambiguous due to lack of unanimously established criteria.